London hospitals seeing sharp rise in respiratory illness

London Health Sciences Centre reports a rapid rise in respiratory illness driven by influenza, recording 163 positive flu tests last week versus seven in the same period a year ago while COVID-19 positives fell to 15 from 67. Officials expect cases to peak earlier (likely late December) with H3N2 dominant; the season’s vaccine is a partial mismatch but still offers roughly 75% protection against pediatric hospital visits and up to 39% for adults. LHSC will require healthcare workers to mask during patient contact from Dec. 15 and is urging vaccination and other prevention measures — policies that could raise short-term hospital utilization and staffing pressure and modestly boost vaccine uptake, but are unlikely to move broader financial markets.

Analysis

MARKET STRUCTURE: An early, H3N2-driven flu surge benefits rapid-diagnostics (Abbott ABT, QuidelOrtho QDEL), vaccine manufacturers (GSK, SNY, CSL.AX) and PPE/filtration suppliers (3M MMM) via near-term volume spikes, while elective-focused hospital operators (HCA) face revenue risk from postponed procedures and higher staffing costs. Pricing power will be strongest for point-of-care antigen/PCR tests (limited marginal cost) and for suppliers with existing government contracts; vaccine makers face mixed pricing if strain mismatch reduces uptake.

RISK PROFILE: Tail risks include a worse-than-expected H3N2 virulence or a supply shortfall for vaccines/antivirals causing policy-driven purchases and price caps; low-probability operational shocks (staffing strikes, supply-chain bottlenecks for vials/adjuvants) could magnify impacts within 2–8 weeks. Immediate effects (days–weeks): diagnostic kit sales and mask demand; short-term (weeks–months): elective procedure softness and outpatient revenue shifts; long-term (quarters): potential re-pricing of vaccine expectations into next season.

TRADE IMPLICATIONS: Favor 1–3 month tactical longs in diagnostics (ABT, QDEL) and PPE (MMM) and short/hedge elective-heavy hospital names (HCA) if utilization metrics deteriorate. Options: use call spreads to capture capped upside in vaccine names (GSK Feb–Mar call spread) and buy 4–8 week puts on HCA sized to offset 1–2% portfolio exposure if weekly flu positivity rises >20% WoW.

CONTRARIAN ANGLES: Consensus may underweight duration — initial spikes often reverse quickly after peak; vaccine makers could underperform because mismatch reduces retail demand even as institutional demand rises. Historical H3N2 seasons (e.g., 2014–15) show policy buying and market volatility; monitor weekly positivity and hospital occupancy—if growth decelerates <5% WoW, close tactical longs within 2 weeks to avoid reversal.

Key Decisions for Investors

• Establish a 2% long position in Abbott Laboratories (ABT) targeting +8–12% within 3 months on higher rapid-test demand; set a hard stop-loss at -6% and add 1:1 Feb call spread (buy Feb 2026 $110 call / sell $120 call) sized to 0.5% notional to leverage upside if weekly flu positives rise >15% WoW.
• Initiate a 1.5% long position in GSK (NYSE:GSK) with a 3–6 month horizon; complement with a Feb–Mar call spread (buy Feb call / sell 1.2x strike) to capture government/seasonal upside while limiting premium outlay; exit if vaccine uptake guidance falls below prior-year volumes by >20%.
• Reduce net exposure to elective-focused hospitals by 1–2% (trim HCA Healthcare HCA) and purchase 4–8 week puts (size to cover 1% portfolio risk) as a hedge; trigger hedge increase (double notional) if local hospital elective cancellations are announced or weekly hospital occupancy increases >10% from baseline.
• Add a 1% tactical long in 3M (MMM) for PPE/filtration demand with a 1–3 month horizon; take profits if PPE order backlog clears or if weekly mask sales data falls below a 10% growth threshold versus prior month.